NanoViricides (AMEX:NNVC) To Start Phase II Oral Ebola Trial in DRC Next Week
NanoViricides, Inc. said a Phase IIA/IIB trial of oral NV-387 gummies for Ebola is scheduled to start next week at an Ebola Treatment Center in Ituri province, DRC.Material DetailsContext by AI AnalystThis is an early-to-mid stage clinical step for NV-387, shifting from platform promises to patient…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.